CompletedNot applicableNCT05807204
Effect of a Multi-ingredient on Visceral Adiposity and Non-alcoholic Fatty Liver Disease in Individuals With Abdominal Obesity
Studying NON RARE IN EUROPE: Non-alcoholic fatty liver disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fundació Eurecat
- Principal Investigator
- Xavier Escoté, PhDEurecat, Technology Centre of Catalonia
- Intervention
- Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine(dietary_supplement)
- Enrollment
- 20 enrolled
- Eligibility
- 40 years · MALE
- Timeline
- 2023 – 2024
Study locations (1)
- Eurecat, Reus, Spain
Collaborators
Centre de Diagnosi per la Imatge · Laboratorio de Referencia Sud · Centro OWLiver
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05807204 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07335198A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European AncestryGlaxoSmithKline
- ACTIVE NOT RECRUITINGNANCT07366710Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PETRigshospitalet, Denmark
- RECRUITINGPHASE4NCT06449833Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLDZhujiang Hospital
- RECRUITINGNANCT06413069Effects of Almonds in Glucose-intolerant Adults (AGAMEMNON)Charite University, Berlin, Germany
- RECRUITINGPHASE1NCT05979389Bicalutamide Therapy in Young Women With NAFLD and PCOSUniversity of California, San Francisco
- RECRUITINGNANCT06704321Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLDValbiotis
- ACTIVE NOT RECRUITINGNANCT06697977Effects of Phytosterol Supplementation on Liver Function and Inflammatory Status in Patients with Nonalcoholic Fatty Liver DiseaseUniversity of Jordan
- RECRUITINGPHASE4NCT05644717Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLDGetz Pharma
See all trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease →